Fresh data support Saxenda's potential
Novo Nordisk has disclosed new phase III data to support the efficacy of the drug group’s obesity contender Saxenda. The data confirm the drug's potential, says an analyst.
BY STEFAN SINGH KAILAY
While Novo Nordisk, analysts and investors alike hold their breath in anticipation of a decision from the US Food and Drug Administration, FDA, on whether or not to approve the company’s obesity contender Saxenda for marketing on the biggest medicine market in the world, Novo has now published fresh data to support the efficacy of the drug.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo chief: I avoided a heart attack
For abonnenter
